Dose Tr Glaukos Corp News Today : Breaking News, Live Updates & Top Stories | Vimarsana

An intracameral implant that releases travoprost into the eye over an extended period to lower intraocular pressure in glaucoma and ocular hypertension will be available commercially in early 2024.

United statesSouth dakotaJohn berdahlDrug administrationAmerican society of cataractGlaukos corpDose tr glaukos corpVance thompson visionSioux fallsAmerican societyRefractive surgeryEfractive eye surgeryIntraocular pressureOp intraocular pressureOcular hypertensionClinical research